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The problem of accurately estimating and characterizing different mutations
in the viral genomes present within a population is of great importance in
tracking and mitigating the spread of the virus and is made difficult by the
lack of a sufficient number of sequenced genomes especially during the early
stages of an outbreak. We consider the problem of determining the muta-
tional support and distribution of mutations in the SARS-Cov-2 genome and
its open reading frames (ORFs). The mutational support refers to the un-
known number of sites that are mutated among all the viral strains present
in a population. The support and distribution of mutations can be used to
guide primer selection for RT-PCR test kits, study the virulence of the virus,
discover adaptation mechanisms deployed by the virus to evade the host
immune system, as well as to identify new strains that might be circulat-
ing in the population early on. We propose new state-of-the-art polynomial
estimation techniques using weighted and regularized Chebyshev approxima-
tions for small-sample mutational support estimation and we use a modified
Good-Turing estimator for distribution estimation. Our differential analysis
of mutations in various population subgroups (based on data retrieved from
GISAID repository) revealed several important differences including those in
the ORF6 and ORF7a regions for older versus younger patients, ORF1b and
ORF10 regions for females versus males and in several ORFs for Asia versus
Europe and North America. We also found no significant mutations in the
primer regions from ORF N chosen by CDC for RT-PCR test kits in any of
the subpopulations, which is important for reliability of the test results.
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Viruses undergo frequent mutations introduced mostly during the replica-
tion of their genetic material, a process that is prone to errors. Some of
these mutations provide survival advantage to the virus by helping it evade
the immune system of the host, thus becoming more widespread in the pop-
ulation. The rates of mutations are different for various different viruses
and have been extensively explored in virology literature in the past [1, 2].
RNA viruses are known to mutate faster than DNA viruses, as are single
stranded viruses compared to double stranded ones. This is due to inaccu-
rate RNA duplication compared to DNA and general structural instability
of single stranded genomes [3]. An inverse correlation between the length
of the viral genome and the rate of mutation has also been documented.
Viruses with shorter genomes mutate much more rapidly than their longer
counterparts [4].
The host immune system has memory of viruses it has already encountered
and if the host is exposed to such a virus, the immune system proceeds swiftly
to eliminate it. However, the virus can mutate and if the rate if mutation
is sufficiently high, it can make it harder for the host immune system to
identify it, thus slowing down the immune response. This phenomenon is
known as antigenic drift. This gives fast mutating viruses more time to
replicate and spread, and by evading the host immune system such viruses
pose a great health risk [5, 6]. On the other hand, some recent studies have
shown that high rates of mutation can also be detrimental to survival of the
virus on short time scales by triggering a rapid innate immune response by
the host [7]. Thus, the mutational landscape of a virus is closely related to
its potential to spread among a population and a virus may need to explore
a significant number of mutations in its attempt to successfully infect a large
number of hosts [8, 9, 10]. However, our understanding of the causes of
elevated mutation rates and their correlation with clinical outcomes is still
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limited. Accurately determining the mutation rates and the distribution
of mutations is an important first step in the direction of addressing these
questions.
A number of different definitions of viral “mutation rate” can be found in
the literature [1, 11]. Genomic mutation rate represents the average number
of positions at which each viral genome differs from its ancestral genome and
is calculated as a product of the per-nucleotide mutation rate and the length
of the genome. The per-nucleotide mutation rate of RNA viruses lies in the
range 10−6 − 10−4 [11]. Even though it is known that replication errors are
not the only source of mutations in viral genomes, replication error rates
and mutation rates of viruses are often used interchangeably. Some studies
estimate the counts of mutations in sequenced genomes using the genomes
of the first infected individual (Patient 0) or, more frequently, the first indi-
vidual that was sequenced (Patient 1) as a reference. The genomic mutation
rate of SARS-Cov-2 is estimated to be 2-3 mutations a month [12]. Since
a large carrier population can harbor viruses with widely different mutation
rates, it is more challenging to define the genomic mutation rate for such a
population.
To define the mutational support of a virus we use the viral genome of
Patient 1 as a reference and index all locations along the genome. The muta-
tional support of a single viral genomic sequence equals the set of locations
where it disagrees with the reference. The size of the mutational support
hence equals the Hamming distance between the reference and the sequence
under consideration. The mutational support of a population (henceforth,
mutational support) of viral genomes equals the size of the union of the in-
dividual mutational supports. Only a subset of the infected patient’s viral
genomes is sequenced at any given time, therefore we do not observe the
mutational support of a population directly and estimation methods need to
be employed. We can count the number of mutations present in at least one
of the sequenced samples, however a simple count based estimator (maxi-
mum likelihood estimator) gives good performance only in cases where the
number of samples sequenced is significantly larger than the length of the
viral genome. In the absence of sufficient number of sequenced samples, the
maximum likelihood estimator may return highly inaccurate estimates due to
unobserved mutations. This phenomenon, known as the small-sample effect,
has been extensively researched in the machine learning community [13, 14].
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Nevertheless, to the best of our knowledge, the problems of mutational sup-
port and mutational distribution estimation in the small-sample regime have
not been addressed in the virology literature. We argue that this problem
is of significant relevance as its successful solution may be used to assess
the virulence of the virus, guide primer selection for real-time RT-PCR tests
during the early stages of an outbreak and correlate mutational rates with
elevated risks of heavy symptoms.
Our contributions are two-fold. First, we present new machine learning
methods for determining the unknown support of mutations and their distri-
butions given sequencing data from a limited number of Covid-19 patients.
The methods use efficient polynomial class estimators and exhibit state-of-
the art performance on synthetic datasets. The actual genomic datasets
are retrieved from the Global Influenza Surveillance Aid (GISAID) reposi-
tory during the early stages of the Covid-19 outbreak. In our initial anal-
ysis, we only use < 9, 000 samples, which is a significantly smaller number
than the length of the SARS-Cov-2 genome which roughly equals 30, 000.
The approach is based on weighted Chebyshev polynomial estimators and
adapted Good-Turing distribution estimators, and its accuracy is evaluated
based on larger sample set sizes retrieved on later dates. Second, the mu-
tational supports are estimated for three different population types, namely
according to geographic region (Asia, Europe, North America (NA)), gender
(female/male) and age (< 55, > 55). For European samples retrieved at a
later time stage, estimates for females of age < 55 versus males of age > 55
were analyzed as well. The estimates are used to predict mutational hotspots
and compare the genomic loci with highest mutation frequency in different
subpopulations. For the latter task, we further process the results by using
the Jaccard distance as well as the symmetric Kullback-Leibler divergence.
Furthermore, to determine if the mutation rates are appropriately low in
genomic regions harboring primers used for real-time reverse-transcriptase
polymerase chain reaction (RT-PCR) testing [15], we separately scrutinize
the N ORF of SARS-Cov-2 samples.
Our analysis reveals several important biological findings. The predicted
mutational supports exhibit significant differences in the ORF6 and ORF7a
regions in older versus younger patients, and in the ORF1b and ORF10 re-
gions in females versus males. The mutational support of the ORF1b region
for young females is almost twice that of old males, while old males have
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a significantly larger mutational supports for genes S and ORF10. Given
that young females are much less likely to develop severe symptoms than
old males, the identified potential high-mutation regions may be further ex-
amined to identify their potential role in the spread and severity/potency of
the virus. Furthermore, it is important to observe that the variance of the
support is extremely high in the ORF8 region, close to 200 times higher for
patients above 55 years of age compared to patients below 55 years of age.
Less surprisingly, there also exist statistically significant differences in the
ORFs of Asian versus European and NA samples in the ORF1a,b and other
ORFs. Second, despite the fact that we predict that the N region of SARS-
Cov-2 will have a very large mutational support, almost all high-probability
mutations fall outside of the two regions of paired primers recommended by
the CDC for RT-PCR testing.
The remainder of the thesis is organized as follows. In Chapter 2, we
describe the data acquisition process, the pre-processing tasks as well as our
new small-sample support and distribution estimation algorithms. Chapter
3 contains the most relevant results and the discussion of their biological




We first describe the organization of the SARS-Cov-2 genome, followed by
the data acquisition from GISAID, data pre-processing as well as the en-
tire work-flow pipeline we developed for our analysis. Finally, we describe
our polynomial based small-sample support estimator and a modified Good-
Turing estimator for distribution estimation.
2.1 Organization of the SARS-Cov-2 genome
A breakdown of the genomic structure of SARS-Cov-2 is depicted in Fig-
ure 2.1, and described in detail in [16] and [17]. Understanding the roles
played by various ORFs of the viral genome is of importance as it allows one
to put the results of the mutational support analysis into proper context:
Mutational variability in certain ORFs of different host subpopulations may
be indicative of different innate immune responses and evading mechanisms



























































Figure 2.1: Organization of the SARS-Cov-2 genome. (Wuhan-Hu-1,
GenBank MN908947)
Typically, coronaviruses have genomes including at least six open reading
frames (ORFs). ORF1a and ORF1b constitute the longest component of
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the genomes and are responsible for encoding two polypeptides, pp1a and
pp1ab, which are jointly used to create a family of NSP proteins. This
family of polypeptides includes replicase-transcriptase proteins, responsible
for promoting cellular mRNA degradation and blocking the translation pro-
cess in host cells, thereby impairing the operation of the immune response
and proofreading. The pp1a/b polypeptides are functionally combined using
proteases, such as the native chymotrypsin-like protease. Viral structural
proteins are encoded by the sgRNA region, and include the ORF2 or spike
(S), ORF5 or membrane (M), ORF4 or envelope (E), and nucleocapsid (N)
proteins, as well proteins encoded by the ORF10 sequence. ORF3a encodes
a membrane protein that interacts with proteins encoded by ORFs M, S and
E and is believed to play an important role in viral release and the generation
of cytokine storm; on the other hand, ORF3b encodes proteins that block
the induction of interferons with antiviral activity. The ORF6 products are
important virulence factors that enable the virus to escape detection by the
immune system of the host.
For real time RT-PCR testing and detection of Covid-19, the oligonu-
cleotide primers and probes are selected from the nucleocapsid (N) gene
region (per CDC guidelines for the United States [18]), and as provided
in panels produced by Integrated DNA Technologies (IDT), including two
primer pairs/probe sets. As a control, additional primer/probe sets are used
such as the human RNase P gene (RP) which is also included in the panel.
Countries like Germany and China have adopted primers from other genomic
regions, as outlined in [15]. For individual testing for Covid-19 in the United
States, it is of special interest to predict mutation rates in the N region of the
genome [15]. High-rate mutations in this region may cause highly undesirable
false negatives in the test outcomes. ORF7a encodes for a membrane protein
while ORF7b is believed to act as a viral attenuation factor and contributor
in human infectivity, similarly to the protein encoded by ORF8. The ORF9b
has the role to impede mitochondrial morphology and function and disable
the interferon response of the host, while ORF9c appears to block important
signaling pathways of the host [17].
6
2.2 Data acquisition
For the proposed analyses, we used data from the GISAID EpiCoV database [19]
which contains sequenced viral strains collected from patients across the
world. We downloaded the data at three time points, starting from 04-
03-2020, continuing on 04-10-2020 and finishing on 04-14-2020. We then
revisited the repository on 10-20-2020 to further evaluate the quality of our
predictions regarding the mutational supports. At that point of time, 9, 271
samples from Asia and more than 30, 000 samples from NA and 85, 000 sam-
ples from Europe were available.
For samples made available in April as well as in September 2020, we
filtered the datasets only to include nearly-complete samples, i.e., those of
length > 29, 000 nts, resulting in a number of samples summarized in Ta-
ble 2.1. We also downloaded the associated metadata used for patient sub-
typing. Note that we used results obtained early in the monitoring process
in order to evaluate our small-sample estimation schemes. Table 2.1 provides
the number of samples available within different categories for each of the
three time points.
Table 2.1: Number of samples available for different phenotype classes and data
retrieved on three different dates, 04-03-2020, 04-10-2020 and 04-14-2020.
Date Age Gender Region Total # of samples
> 55 < 55 Male Female Asia Europe NA
04-03 909 1,477 1,349 1,061 510 1,695 818 3,511
04-10 2,373 1,850 2,315 1,956 615 3,194 1,147 5,650
04-14 3,047 3,231 3,526 2,817 636 5,890 1,774 8,893
As the first step in our analysis, we used the sequence alignment soft-
ware MUSCLE [20] to perform pairwise alignment of all the samples with
the SARS-Cov-2 sequence of Patient 1, published under the name Wuhan-
Hu-1, admitted to the Central Hospital of Wuhan on December 26, 2019
(GenBank accession number MN909847). Furthermore, we also performed
alignment with respect to Patient 1 of two additional continents, Europe
and NA. The latter alignment was performed to better determine how the
mutational support and mutational distribution depends on a particular ge-
ographic context.
For each aligned pair of samples, we generated a “mutation profile,” a list
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containing the positions in the reference genome in which the patient aligned
to the reference has a substitution mutation. We did not perform multiple
sequence alignment in order to assess the mutation landscape as we need to
analyze each patient data separately (each patient and her/his mutations are
treated as one sample in the estimation procedure). The mutational profile
lists are subsequently aggregated over all the patient samples, resulting in
a histogram of mutations across all positions in the viral reference genome.
The aggregate profiles are further partitioned according to the 11 genes they
are located in on the viral genome depicted in Figure 2.1. The total count
of mutations for each location in each gene is used as a sufficient statistic for
estimating the mutational support and the distribution of the mutations in
each of the 11 genes. The analytic pipeline used is depicted in Figure 2.2.
Figure 2.2: The data analysis flowchart: Viral sequencing data is retrieved
from the GISAID repository and then aligned against the genome of
Patient 1 or regional Patient 1 in a pairwise fashion. The substitutions at
different genomic locations for all analyzed pairs of samples are counted
and used as sufficient statistics for the estimation procedures.
To adjust for alignment artifacts introduced by sequencing errors, dropouts
and alignment gaps, we removed all gaps encountered in the prefixes and
suffixes and sufficiently long gaps (> 10 nts) within the actual alignments.
Most gaps are encountered at the 5’UTR and 3’UTR regions of the genome,
as may be expected from outputs of global alignment algorithms.
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As there exists a large body of evidence of stratified susceptibility and
severity of symptoms across different racial, age and gender groups [21, 22],
we performed four different types of mutational support and distribution
analyses. In the first set of tests, we split the patient mutation histograms
based on gender (male/female), based on age (under 55/over 55) and based
on the geographic location (Asia/ NA/ Europe). The age threshold was set
by taking into consideration available sample sizes needed for the analysis
and the age profile of patients available on GISAID; the threshold also reflects
different risk groups for the development of severe symptoms. In addition,
we performed the same analysis for a combination of patient features for
settings with sufficiently many samples available early in the pandemic, such
as males above 55 years of age/females below 55 years of age, from Europe.
Note that in all the described cases, “geographic location” refers to the region
of infection of the patient and not the region where he/she was tested and
the sample was sequenced.
Since the number of samples per population type may vary significantly,
we performed two tests. In one test we used all samples available, while
in another we adjusted for difference in sizes of the sets by subsampling the
larger of the two classes to make the sample sets of equal sizes. The number of
samples available for various patient subgroups is listed in Table 2.1. For data
obtained on 04-03-2020, we used all the samples available for all the classes,
without balancing the class sizes. For data retrieved on 04-10-2020 and 04-
14-2020, we balanced the classes by subsampling from the larger of the two
classes for both age- and gender-based subtypes. For different geographical
regions, on 04-10-2020, we used all 615 samples from Asia and subsampled
Europe and NA to 1000 samples each. Similarly, we used all 636 samples
from Asia and subsampled Europe and NA to 1, 774 samples each, for data
retrieved on 04-14-2020. It is important to point out that by performing
the experiments with different sample set sizes one can compare the quality
of the estimates obtained using samples from the early stages of epidemics
and those obtained from later stages when more information about individual
viral sequences is available. Furthermore, the new machine learning methods
outlined in Sections 2.3 and 2.4 apply to any other viral or bacterial dataset
collection with the obviously required modifications to account for the genetic
profile of the microorganisms.
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2.3 New small-sample support estimators
We focus on the polynomial approximation approach put forward in [23], and
significantly improve on it in practice by introducing new weighted Cheby-
shev polynomial optimization techniques largely unknown in the machine
learning and computational biology community [24]. The weighted approx-
imation method can be seamlessly combined with regularization techniques
that use the variance of the estimator in a way that complements features
used in maximum likelihood (ML) estimation [25]; and with semi-infinite
programming (SIP) solvers that produce the parameters of the estimator.
The SIP methods can be solved consistently and highly efficiently through
discretization resulting in a small linear program (LP) of size decreasing with
the number of samples. Interestingly, despite the fact that our estimators are
constructed using an LP as is the case for the best performing ML-based ap-
proach [26], the ML-LP formulation has a number of variables and constraints
that actually increase with the number of samples; this difference makes our
estimator significantly more efficient as is needed for large scale estimation
processes like the ones described in this work, in addition to improving their
performance.
Next, we provide a detailed description of our polynomial estimation method.
Recall that the support of a discrete probability distribution is defined as the
number of symbols with positive probability of occurrence. We define the
mutational support of a virus as the total number of genomic sites mutated
in any viral genome in any individual (observed or unobserved due to lim-
ited testing), compared to a reference genome. As already pointed out, in our
case the reference is the genome of Patient 1, the first sequenced SARS-Cov-2
genome or the genome of regional Patient 1.
The most commonly used techniques for support and distribution estima-
tion are ML methods which directly use the empirical counts of the symbols
to determine the support or probabilities of interest. It is well known that
ML approaches perform poorly for large alphabet sizes (supports) when only
a small number of samples from the distribution is available. In this case,
they fail to account for samples that have never been observed due to limited
sampling. To see why this is the case, assume that we observe 10 samples
from a distribution supported on {1, . . . , 100}. Clearly, with only 10 samples
available, our best possible guess for the support size will be the number of
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distinct symbols observed which is a number ≤ 10 and far from the correct
value 100.
The problem of estimating the support of an unknown probability distri-
bution or estimating the distribution itself in the context of small-sample
sets has a long history. The first line of work in this area is attributed to
Laplace, as described in [27], who introduced a class of smoothed distribu-
tion estimators termed add 1 (or more generally, add constant c estimators).
These estimators adjust the counts of observed symbols in order to account
for the unseen symbols.
Let P = (p1, p2, . . .) be a discrete distribution over some finite alphabet
and let xn be a vector of i.i.d. samples drawn according to the distribu-
tion P . The problem of interest is to estimate the support size, defined as
S(P ) =
∑
i 1{pi>0}. We use S instead of S(P ) to avoid notational clutter.
An important assumption used in our estimation methods is that the mini-
mum non-zero probability of the distribution P is greater than 1
k
, for some
k ∈ R+, i.e., inf{p ∈ P | p > 0} > 1
k
. We let Dk denote the space of all prob-
ability distributions satisfying inf{p ∈ P | p > 0} > 1
k
. A sufficient statistic
for xn is the empirical distribution (i.e., histogram) n = (n1, n2, . . .), where
ni =
∑n
j=1 1{xj=i} and 1A stands for the indicator function of the event A.
To determine the quality of an estimator, we use the most frequently stud-
ied risk model, the minmax risk under normalized squared loss, defined as





























The first term within the supremum captures the expected bias of the estima-
tor Ŝ. The second term represents the variance of the estimator Ŝ. A“good”
estimator should jointly balance out the worst-case contributions of the bias
and variance (note that for the case that only the bias is considered directly,
and the variance accommodated for by modifying the bias-optimized solu-
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tion, the underlying estimator was analyzed in [23]).
To introduce our method, we first describe the class of polynomial estima-
tors. Given a positive integer parameter L, we say that an estimator Ŝ is
a polynomial class estimator with a threshold parameter L (i.e., a Poly(L)
estimator) if it takes the form Ŝ =
∑
i gL(ni), where gL is defined as
gL(j) =
ajj! + 1, if j < L1, otherwise. (2.3)
The coefficients a satisfy aj ∈ R and a0 = −1, (since this choice ensures that
gL(0) = 0) and have to be optimized in order to minimize the risk. One can
associate an estimator Ŝ with its corresponding coefficients a, i.e.,
Poly(L) =
{
a ∈ RL+1|a0 = −1
}
.
The authors of [23] proposed using a special form of polynomial estimators
in which the coefficients aj correspond to scaled evaluations of a Chebyshev
polynomial of order L. The Chebyshev polynomial of the first kind of degree
L is defined as




where z is the solution of the quadratic equation z + z−1 = 2x. The polyno-
mial TL is bounded in the interval [−1, 1] and may be scaled and shifted to













Clearly, RL(0) = −1 and ã0 = −1.












ãjj! + 1, if j < L,1, otherwise, (2.5)
with L , bc0 log kc, [l, r] ,
[n
k
, c1 log k
]
. (2.6)
The choice values of the constants c0 and c1 are c0 = 0.558 and c1 = 0.5
and they are obtained based on an analysis of the bias and variance of the
estimator.
The estimator S̃ above is order-optimal in the exponent under the unbi-
ased risk. Thus, the estimator can be improved by selecting coefficients of
Poly(L) that jointly optimize the bias and variance term in the risk. We show
how to accomplish this task by rewriting the original minmax problem as a
regularized exponentially weighted Chebyshev approximation problem [24].
In order to jointly optimize the bias and variance term in the squared loss,
































where PL(λ, a) ,
∑L
l=0 alλ







































In the above inequality, we used the Cauchy-Bunyakovsky-Schwarz inequal-






> 0, for all λ > 0. Hence,
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Problem (2.7) represents an instance of a regularized weighted Chebyshev












The term e−λPL(λ, a) corresponds to the bias of the estimator. It is straight-





























Diag(λ00!, λ11!, ..., λLL!).
Clearly, ||.||M(λ) is a valid norm, and consequently, the first term in (2.7) can
be viewed as a regularizer.



























where (2.9) is equivalent to (2.8), while (2.10) resembles the problem studied
in [23], except for a different optimization interval used within the supremum
(the authors of [23] choose a shorter interval in order to decrease the contri-
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bution of the variance to the loss). Hence, optimizing (2.9) should produce
an estimator with smaller bias as the exponential weight is inherent to the
formulation. The modified bound in (2.10) is minimized with respect to the
coefficients a, using the minmax property of Chebyshev polynomials [28, 29],
resulting in ã.
To solve (2.7), we more closely examine some results known about weighted
Chebyshev approximations [29] and semi-infinite programs. Solving for the
problem directly is difficult, so we instead resort to numerically solving the
epigraph formulation of problem (2.7) and proving that the numerical solu-
tion is asymptotically consistent.















≤ t,∀λ ∈ [n
k
, n],with a0 = −1.
(2.11)
Note that (2.11) is a semi-infinite programming problem. There are many
algorithms that can be used to numerically solve (2.11), such as the dis-
cretization method, and the central cutting plane, KKT reduction and SQP
reduction methods [31, 32]. For simplicity, we focus on the discretization
method. For this purpose, we first form a grid of the interval [n
k
, n] involv-
ing s points, denoted by Grid([n
k
, n], s). Problem (2.11) may consequently
be viewed as an LP with infinitely many quadratic constraints, which is not




















, n], s),with a0 = −1.
(2.12)
The solution of the relaxed problem is asymptotically consistent with the
solution of the original problem (i.e., as s goes to infinity, the optimal values of
the objectives of the original and relaxed problem are equal). Problem (2.12)
is an LP with a finite number of quadratic constraints that may be solved
using standard optimization tools. Unfortunately, the number of constraints
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scales with the length of the grid interval, which in the case of interest is linear
in n. This is an undesired feature of the approach, but it may be mitigated
through the following theorem which demonstrates that an optimal solution
of the problem may be found over an interval of length proportional to the
significantly smaller value log k, where k
log k
. n is the fundamental bound
for support estimation. We relegate the proof to Appendix A.




















supλ∈[nk ,6.5L] g(a, λ) if nk ≤ 6.5Lg(a, nk ) if nk > 6.5L.
Remark. In weighted approximation theory [24], the problem of bounding
the interval over which the supremum is achieved is a topic of significant
interest, with many important available results. For example, if we ignore
the regularization term, we can directly use the Mhaskar-Saff theorem to
reduce the length of the interval in the supremum to π
2
L. Our Theorem
shows that even when a regularization term is present, we can still restrict
the length of the interval to 6.5L. Our proof differs from that of the more
general Mhaskar-Saff theorem, since we exploit the specific structure of the
problem.



















, 6.5L], s),with a0 = −1.
(2.13)
Since L = bc0 log kc, the length of the optimization interval in (2.13) is
proportional to log k.
It seems intuitive to assume that as s grows, the solution of the relaxed
16
semi-infinite program approaches the optimal solution of the original prob-
lem (2.11). This intuition can be rigorously justified for the case of objective
functions and constraints that are “well-behaved,” as defined in [33] and [34].
The first line of work describes the conditions needed for convergence, while
the second establishes the convergence rate given that the discretized solver
converges. We use these results in conjunction with a number of properties
of our objective SIP to establish the claim in the following theorem. The
proof is relegated to Appendix A.
Theorem. Let s be the number of uniformly placed grid points on the inter-
val (2.13), and let d ,
6.5L−n
k
s−1 be the length of the discretization interval.
As d → 0, the optimal objective value td of the discretized SIP (2.13) con-
verges to the optimal objective value of the original SIP t?. Moreover, the
optimal solution is unique a?. The convergence rate of td to t
? equals O(d2).
If the optimal solution of the SIP is a strict minimum of order one (i.e., if
t−t? ≥ C||a−a?|| for some constant C > 0 and for all feasible neighborhoods
of a?), then the solution of the discretized SIP also converges to an optimal
solution with rate O(d2).
In summary, for given parameters k and n, and sample count histogramsN ,
we obtain the optimal coefficients of our polynomial estimators by solving the
small LP program described above. An example of our polynomial estimator
(henceforth termed Regularized Weighted Chebyshev (RWC) estimator) and
its scaled coefficients gL is shown in Figure 2.3, along with a corresponding
example of a Chebyshev estimator (termed the Wu-Yang (WY) estimator).
It is easily observed that the coefficients of the two estimators exhibit very
different behaviors: Unlike the Chebyshev case, for which the coefficients
have to alternate in sign, our estimators are not constrained to obey this
pattern.
Remark. It is important to point out that the RWC estimators are “ad-
ditive”: They operate on each symbol separately and the contributions of
symbols are linearly combined to obtain the overall support estimate.
We conclude by observing that our RWC estimator can be further (heuris-
tically) improved in practice by optimizing it with respect to a minmax risk
that involves a different scaling factor in the denominator. This estimator,
termed the RWC-S estimator (to indicate that the scaling is performed us-
ing the result of a naive support estimator) is described in more detail in
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Figure 2.3: The function gL for RWC and WY estimator. The parameter
setting used for the illustration is n = k = 106 and c0 = 0.558.
Appendix A.
2.4 Small-sample distribution estimation
By far the most frequently used method for distribution estimation in the
small-sample regime is the Good-Turing estimator [13], which tries to account
for the unseen by adjusting the counts (histograms) of the actually observed
symbols. In a slightly modified form the method may be described as follows.
For a sequence xn of length n over an unknown finite alphabet, we once again
let ni denote the number of times a symbol i appears in x
n. Furthermore,
we let ϕt stand for the count of counts, i.e., the number of symbols that
appear t times in xn. The estimator proposed in [14] combines the Good-
Turing and ML estimators, the latter being used for the frequently observed
symbols. For symbols that appear t times, if ϕt+1 > Ω(t), then the Good-
Turing estimate is used to determine the underlying total probability mass,
otherwise the ML estimator is used instead. More precisely, for a symbol
appearing t times, if ϕt+1 > t we use the Good-Turing estimator, otherwise
we use the ML estimator. If ni = t, the estimated probability of the symbol
i is computed according to
pi =






where η is a normalization term that ensures that the obtained values are
probability masses. The term ϕt+1 used in the Good-Turing estimator is
replaced by ϕt+1 + 1 so that every symbol has a nonzero probability.
The modified Good-Turing estimator is used instead of the classical Good-
Turing estimator as the latter is known to poorly estimate the probabilities
of high frequency symbols. Modifications of the Good-Turing estimator that
take sampling artifacts/errors into account are also available, and are imple-
mented as described in [35, 36].
2.5 The performance of RWC estimators on synthetic
data
Consider a finite alphabet S = {1, . . . , S}. Assume that the probability of
symbol i ∈ S equals pi and that you can randomly sample symbols from
the alphabet with replacement and record the distribution histogram of N
observed symbols. The question of interest is how accurately one can estimate
S based on N samples and the parameter k dictating the smallest nonzero
probability of the distribution.







, i ∈ {1, 2, · · · , 10}.
Clearly, S = 10 and k = 55. For the RWC and RWC-S estimators, we
choose L = b0.558 log kc = 2. Now assume we draw n = 6 samples from the
alphabet according to the specified distribution. In this case, the values of
gL for the RWC-S estimator are given in Table 2.2.
Table 2.2: The gL values corresponding to the RWC-S estimator for
different distinct symbol counts: Note that Ŝc denotes the naive estimator
(i.e., the estimator equal to the count of different symbols).
Ŝc = 1 Ŝc = 2 Ŝc = 3 Ŝc = 4 Ŝc = 5 Ŝc = 6
gL(0) 0 0 0 0 0 0
gL(1) 1.8128 2.4819 2.9427 3.2422 3.4367 3.5758
gL(2) 1.8128 2.3967 1.7205 1.0699 0.5556 0.1663
gL(j),∀j ≥ 3 1 1 1 1 1 1
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Consider all possible histograms of n = 6 symbols in this setting, sum-
marized in Table 2.3. We can clearly see that except for the case N =
[1, 1, 1, 1, 1, 1], our estimator provides a significantly better support estima-
tion result. Note that the histogram N = [1, 1, 1, 1, 1, 1] arises only with
very small probability (9%), and this probability significantly decreases as
n, S, k increase. Nevertheless, even in this case, the risk (mean-square error
normalized by S2) of our RWC-S estimator equals 0.2186 while that of the
naive estimator equals 0.319.
Table 2.3: The estimated supports produced by the RWC-S and naive estimators
for all possible histogram inputs. The probability of each histogram is computed
via a Monte Carlo method with 106 independent trials. Bold numbers indicate
the best estimation result compared to the ground truth.
Histogram N [1,1,2,2] [1,1,1,1,2] [1,1,1,3] [1,2,3] [1,5] [1,1,4]
RWC-S 8.6242 14.3034 10.7266 5.6632 3.4819 6.8854
Naive 4 5 4 3 2 3
Probability 0.2633 0.3792 0.1374 0.0801 0.0021 0.0253
Histogram N [2,2,2] [3,3] [2,4] [6] [1,1,1,1,1,1]
RWC-S 5.1615 2 2.7205 1 21.4548
Naive 3 2 2 1 6
Probability 0.0171 0.0025 0.0043 0.0001 0.0886
We also tested the performance of the estimators on significantly larger
sets of synthetic data for which the ground truth distributions and their
supports are known. In particular, we compared the RWC method with the
Good-Turing (GT) estimator, the WY estimator of [23], the PJW estimator
described in [37] and the HOSW estimator of [38]. We did not compare
our method with the estimators introduced in [26, 39] due to their high
computational complexity [38].




, the Zipf distributions with pi ∝ i−α, and α equal to 1.5, 1, 0.5 or
0.25, and the Benford distribution with pi ∝ log(i + 1) − log(i). We choose
the support sizes for the Zipf and Benford distribution so that the minimum
non-zero probability mass is roughly 10−6. We run the estimator 100 times
to calculate the risk. For both approximation-based estimators, we fix c0 to
be 0.558. With our proposed method, we solve (2.13) on a grid with s = 1000
points on the proposed interval [n
k
, 6.5L]. For the estimator described in [23],
we set c1 = 0.5 according to the recommendation made in the cited paper.
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(a) Worst case MSE/k2.
































(b) Worst case MSE/S2.



















(c) RWC (weighted) versus classical Cheby-
shev approximation.
Figure 2.4: Comparison of worst case risks for different ground truth
distributions and estimators. In our simulations we set n = k = 106 and
c0 = 0.558.
The GT method used for comparison first estimates the total probability
of seen symbols (e.g., sample coverage) according to Ĉ = 1 − h1
n
, and then
estimates the support size according to ŜGT =
Ŝc
Ĉ
; here, Ŝc stands for the
(naive) counting estimator. Note that h1 equals the number of different
alphabet symbols observed only once in the n samples.
Figure 2.4(a) shows that the RWC estimator has a significantly better
worst-case performance than all other methods when tested on the above
described collection of distributions, provided that n ≥ 0.2k. Also, both
RWC and WY estimators have significantly better error exponents compared
to the GT, PJW and HOSW estimators. The GT and PJW estimators
perform better than RWC if n . k
log k
, which confirms the results of our
theoretical analysis as well.
In the second set of experiments, we change the normalization from (1/k)2
21
to (1/S)2 as was also done in [38]. The RWC-S estimator minimizes an upper





. As already pointed out, a detailed
description of this algorithm and an intuitive explanation of why it outper-
forms the RWC method is provided in Appendix A. Figures 2.4(b) illustrate
that our RWC-S estimator significantly outperforms all other estimators with
respect to the worst-case risk normalized by S2. Moreover, the RWC-S esti-
mator outperforms all known estimators on almost all tested distributions.
As illustrated in Figure 2.4(c) we see that a classical Chebyshev approxima-
tion introduces a larger bias than our RWC method whenever the underlying
distribution is close to uniform (i.e., when λ ∼ n
k
= 1). This phenomenon
persists even when regularizations is taken into account.
Another common approach to testing support estimators on real data is to
estimate the number of distinct words in selected books [26, 23]. Books are
chosen as ground truth test cases as the words in a text are not independent
and identically distributed (i.i.d.) and hence provide a means to test the
performance of estimators optimized for i.i.d. settings. The performance of
our approach and those of prior works on Hamlet and Macbeth can be found
in Appendix B. In the experiments, we randomly sampled words in the
text with replacement and used the obtained counts to estimate the number
of distinct words. For simplicity, we set k to the total number of words.
For example, as the total number of words in Hamlet equals 30, 364, we set
k = 30, 364. Once again, our method significantly outperforms all other
competitive techniques both in terms of convergence rate and the accuracy
of the estimated support for all experiments.
The details about data acquisition pipeline, alignment software and imple-






We proceed to apply our small-sample support and distribution estimation
methods on GISAID SARS-Cov-2 genomic datasets. The underlying assump-
tion is that there exists a “ground truth” distribution of mutations, and that
most of the mutations cannot be observed due to limited testing. Our studies
of the mutational support and mutation distribution are conducted for dif-
ferent patient subpopulations and all ORFs separately in order to determine
potential subpopulation differences. As already pointed out, the estimators
to be used are additive implying that estimates for individual genes may be
summed to obtain the estimate for the whole genome.
First, we observe that by the last small-sample data collection date re-
ported in this thesis, 04-14-2020, the average number of mutations with
respect to the reference was 7.93 (for male patients) and 7.96 (for female
patients). This difference is statistically insignificant. For patients older
than 55 years, this number was 7.33 while for those younger than 55 the
recorded values were significantly higher, amounting to 8.377. For three dif-
ferent continents, Asia, Europe and NA, the average number of mutations
recorded equaled 13.51, 6.67, and 6.68, respectively. The average number of
mutations per patient in Asia is almost twice as large as the corresponding
numbers in Europe and NA, which is indicative of the fact that the outbreak
started in Asia and that the virus may have been present in the population
significantly longer than in Europe and NA. In all cases, the total number
of recorded mutations across all patients is too small to allow for accurate
prediction of the actual mutational support using frequency methods.
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3.1 Mutational support estimation
The first set of results pertains to data collected at a very early stage of
the pandemic (04-03-2020) that did not include sufficiently many samples to
allow for sample set sizes to be evened out through subsampling. Therefore,
for this analysis, all available samples are included, which may create biases
due to sample set size differences. The results are listed in Tables 3.1, 3.2 and
3.3. They illustrate the difference in the support estimates for two different
age groups, genders and three geographic regions. The nonuniform sample
size artifacts do not obscure the most important findings regarding mutation
rates in different genes across different age groups, gender and geographic
region - the same trends persist even when significantly more samples are
used in the analysis, as described next.
Table 3.1: Support sizes of different age groups based on 909 samples for
individuals over 55 years of age and 1, 477 samples below 55 years of age. The
data was obtained from GISAID by 04-03-2020 and includes all the samples for
the two categories available at the given date. ORF1ab and N are shown in
bold due to their large length and relevance in testing, respectively.
Gene ML RWC RWC-S Maximum Support
Symbol > 55 < 55 > 55 < 55 > 55 < 55 All Ages
ORF1a 625 764 1,280 1,544 1,209 1,454 13,203
ORF1b 276 616 570 1,301 514 1,223 8,087
S 160 218 291 420 277 375 3,822
ORF3a 55 73 103 132 92 121 828
E 14 13 23 23 23 22 228
M 34 35 58 63 54 55 669
ORF6 11 25 19 42 19 42 186
ORF7a 24 27 41 45 39 44 366
ORF8 340 340 87 344 235 343 366
N 66 110 108 197 97 172 1,260
ORF10 26 29 29 53 33 53 117
Tables 3.4, 3.5 and 3.6 list the results analogous to those reported for 04-
03-2020, obtained using datasets retrieved on 04-10-2020. The datasets were
sufficiently large to allow for random subsampling to obtain equal sample set
sizes for all subpopulations considered (excluding Asia).
Based on the results of Table 3.4, we see that the mutational supports in
populations of different age (cutoff at 55 years) differ substantially for the
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Table 3.2: Support sizes based on 1, 349 male and 1, 061 female samples. The data
was obtained from GISAID by 04-03-2020 and includes all the samples for the two
categories available. ORF1ab and N are shown in bold due to their large length
and relevance in testing, respectively.
Gene ML RWC RWC-S Maximum Support
Symbol Male Female Male Female Male Female Both Genders
ORF1a 854 702 1,807 1,468 1,702 1,388 13,203
ORF1b 348 594 690 1,307 640 1,234 8,087
S 225 186 447 359 405 329 3,822
ORF3a 68 61 132 111 115 99 828
E 18 10 30 18 29 18 228
M 37 36 62 68 57 60 669
ORF6 13 27 22 49 21 50 186
ORF7a 32 21 55 38 53 38 366
ORF8 340 341 344 592 343 458 366
N 96 85 165 143 146 129 1,260
ORF10 26 10 30 17 29 17 117
Table 3.3: Support sizes for different geographical regions based on 510 samples
from Asia, 1, 695 from Europe and 818 from NA. The data was obtained from
GISAID by 04-03-2020 and includes all the samples for the three categories
available at the given date. ORF1ab and N are shown in bold due to their large
length and relevance in testing, respectively. Maximum support for all the genes
is the same as shown in previous tables.
Gene ML RWC RWC-S
Symbol Asia Europe NA Asia Europe NA Asia Europe NA
ORF1a 770 757 397 1,645 1,558 776 1,603 1,455 720
ORF1b 279 590 205 566 1,251 372 553 1,159 345
S 168 181 131 321 345 254 313 309 230
ORF3a 84 62 38 158 113 71 154 100 63
E 37 11 6 66 19 9 65 19 9
M 30 29 15 53 49 25 50 44 24
ORF6 2 28 5 2 46 8 2 45 7
ORF7a 108 38 49 215 66 90 214 65 89
ORF8 340 27 19 341 46 26 342 43 28
N 53 90 68 93 152 122 85 137 114
ORF10 10 25 9 18 28 15 17 27 14
ORF3a, ORF6 and ORF7a regions (note that ORF1ab and N are shown in
bold in every table due to their large length and relevance in testing, re-
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Table 3.4: Support sizes of different age groups based on 1, 850 samples from
each group. The data was retrieved from GISAID on 04-10-2020. The
mutational supports between the two groups differ substantially for the genes
shown in italics. ORF1ab and N are shown in bold due to their large length
and relevance in testing, respectively.
Gene ML RWC RWC-S Maximum Support
Name > 55 < 55 > 55 < 55 > 55 < 55 All Ages
ORF1a 996 934 2,039 1,857 1,896 1,743 13, 203
ORF1b 499 484 991 965 924 896 8,087
S 265 279 490 547 458 501 3,822
ORF3a 104 79 188 138 171 124 828
E 23 19 36 33 36 32 228
M 55 47 98 86 92 77 669
ORF6 38 26 65 43 64 41 186
ORF7a 60 31 108 50 103 49 366
ORF8 340 341 93 342 236 343 366
N 140 163 248 294 223 265 1,260
ORF10 31 28 35 49 39 50 117
Table 3.5: Support sizes for different genders based on 1, 956 samples for each
group. The data was retrieved from GISAID on 04-10-2020. The mutational
supports between the two groups differ substantially for the genes shown in italics.
ORF1ab and N are shown in bold due to their large length and relevance in testing,
respectively.
Gene ML RWC RWC-S Maximum Support
Name Male Female Male Female Male Female Both Genders
ORF1a 1,071 1,115 2,176 2,313 2,055 2,175 13,203
ORF1b 500 804 1,013 1,721 941 1,621 8,087
S 283 293 551 562 509 519 3,822
ORF3a 114 99 216 175 190 158 828
E 24 14 37 23 36 22 228
M 52 56 87 101 82 94 669
ORF6 42 30 75 51 74 50 186
ORF7a 42 51 74 87 71 84 366
ORF8 341 342 344 345 344 345 366
N 143 162 251 282 226 259 1,260
ORF10 29 12 33 20 32 19 117
spectively). For ORF7a, the older population exhibits almost twice as many
mutations as the younger population, while for ORF6 and ORF3a the cor-
responding numbers are 1.5 and 1.4, respectively; the estimated mutational
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Table 3.6: Support size for three different geographic regions based on 615
samples from Asia and 1, 000 samples from Europe and NA each. The data was
retrieved from GISAID on 04-10-2020. The mutational supports between the
three groups differ substantially for the genes shown in italics. ORF1ab and N
are shown in bold due to their large length and relevance in testing, respectively.
Maximum support for all the genes is the same as shown in previous tables.
Gene ML RWC RWC-S
Name Asia Europe NA Asia Europe NA Asia Europe NA
ORF1a 827 504 470 1,768 975 948 1,725 919 874
ORF1b 308 271 244 631 531 478 611 491 432
S 182 163 142 352 336 269 340 293 243
ORF3a 91 56 39 174 96 74 168 85 63
E 37 12 14 66 21 24 65 21 24
M 31 23 17 55 38 28 52 35 27
ORF6 3 48 15 3 87 26 3 86 25
ORF7a 109 63 51 216 118 94 214 116 93
ORF8 340 19 21 335 29 31 339 29 31
N 58 72 77 96 121 137 91 108 129
ORF10 10 26 7 18 48 10 17 48 10
supports of the ORF6 and ORF7a regions are close to 1/3 of the whole gene
length for individuals older than 55 years. The mutational differences in the
ORF6 and ORF7a region persist with an increase in the number of samples
(see the Additional Table C.1), with an estimated mutational support for
the former region equal to almost 1/2 of the gene length. Furthermore, addi-
tional differences are observed in the M region which were not apparent when
using smaller sample set sizes. The protein encoded by ORF6 was studied
in depth during the SARS epidemics [40] and it has been established that
the ORF6 protein impairs the nuclear import complex formation (control-
ling the transport of innate immune regulatory cargo to the nucleus of cells
capable of increasing antiviral defenses). The protein encoded by ORF7a
has been implicated in inhibiting bone marrow stromal antigen 2 virion teth-
ering [41]. Bone marrow stromal antigen 2, also known as tetherin, is an
interferon-induced protein which, when expressed, reduces the release of en-
veloped viral particles. The significant number of predicted mutations in the
ORF7a region of older patients suggests a similar observation as that made
for the ORF3a region - a possible effort by the virus to disable or strongly
impair the function of the tetherin antigen.
27
The results pertaining to female/male patients differ significantly from
those pertaining to different age groups. The results are listed in Table 3.5,
and imply strong differences in the mutation rates of the ORF1b and ORF10
regions. The mutational support of ORF1b in the female population is 1, 621
compared to 941 in the male population, which amounts to a 8.4% difference
with respect to the length of the ORF. A similar result is true for the ORF10
region, for which no well-understood functions are known. Some recent re-
sults suggest, based on different evidence, that ORF10 encodes a functional
protein in SARS-CoV-2 and that positive selection is driving the evolution
of this region [42].
The above described differences persist with increased sample set sizes.
The estimated mutational support for ORF1b is 24% and 16% of the length
of the region, and for ORF10 18% and 32% of the length of the region, for
females and males, respectively (see the Additional Table C.2). Smaller yet
possibly relevant differences are also observed for the ORF3a and M regions,
but these do not persist with increased sample set sizes.
For samples obtained from Asia, Europe and NA the results show that
despite the number of samples for Asia being significantly smaller than that
of Europe and NA, the predicted mutational support in all regions is signif-
icantly higher except for the N and ORF6 genes (with only 3 mutations ob-
served in the ORF6 gene). This is particularly the case for ORF3a and ORF8,
where the mutation rates are more than 2 and 10-fold higher in Asian pa-
tients, respectively. It is reasonable to assume that these regions are mutated
early on in an epidemic and tend to “accumulate” the number of mutations.
Also, the significant differences suggest that the epidemic started significantly
earlier in Asia than Europe and NA. The ORF3a region is known to encode
for a protein that activates the NLRP3 inflammasome [43]. ORF3a proteins
are activators of pro-IL-1β gene transcription and protein maturation that
trigger activation of the NLRP3 inflammasome. The inflammasome has a
dual role of boosting the host defense and driving pathologic inflammation.
Based on our findings, one possible explanation for the high mutation rate in
this region in older populations is that the virus trying to disable the host’s
immune system and increase its virulence. Recent results show that the
ORF8 protein may be acquired from SARS-related coronaviruses present in
bats [44], which could explain the large difference in the mutational support
through “adaptation” in a human host (for patients in Asia). The increase
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in the number of samples available for analysis shows that significant dif-
ferences in the mutation support of the E, M, ORF6, ORF7a and ORF10
regions exist as well.
Additional Tables C.1, C.2 and C.3 show the trends of increase for the
mutational support with increased sample sizes. For data collected by 04-
14-2020, this includes roughly 9, 000 samples. All sample set sizes used are
equal (except for Asia, for which the sample set sizes available are signifi-
cantly smaller), therefore allowing for fair comparisons. Additional Table C.1
illustrates that when the sample set sizes are equal, no significant differences
are observed in the mutational supports of disparate age groups except in
the E, ORF6, ORF7a and ORF8 regions. Given that the difference in the
number of mutations in the ORF7a regions persists for several data acquisi-
tion dates, the finding appears to be sample-size independent. On the other
hand, the significant differences in the number of mutations in the E region
is only evident when sufficiently many samples are available. The E region
contains the code for the encapsulation protein of viral RNA, in addition to
some spike proteins. In older subjects, this region is subjected to a signif-
icantly larger number of mutations than in other groups. This may imply
that immunity in elder patients may be dependent on generating antibodies
for the encapsulation proteins. Clearly, no conclusive explanation is possible
based on limited data sets but the results suggest performing further sam-
pling and analysis for this particular ORF in older patients. Although it has
been observed that the immune responses of individuals vary significantly
due to the initial viral load, physical health, and the hosts microbiome, no
definite link between these features and the mutation rates in the above re-
gion can be established due to lack of supporting clinical data at GISAID
and other Covid-19 data repositories.
Additional Table C.2 illustrates surprisingly few differences in the muta-
tional supports of male and female patients once a sufficiently large number
of samples is available: Exceptions are the ORF1b and ORF10 regions. For
different geographic regions, the most significant difference observed pertains
to the ORF8 region, where samples from Asia exhibit a roughly one order
of magnitude larger number of mutations compared to those for samples se-
quenced in Europe and NA. There also exists a marked difference in the
mutational support of ORF7a between patients from Europe on one side and
patients from Asia and NA on the other (i.e., a roughly two-fold difference
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for Europe and NA).
Figure 3.1: Support sizes for all genes and for different groups along with
their standard deviation estimates. The estimates are based on data
collected by 04-14-2020 and should provide the most accurate assessment of
the mutation rate in the small-sample regimes investigated. Estimates are
based on 3, 047 samples each for patients above 55 and below 55 years of
age, 2, 817 samples each for male and female patients and 1, 774 each for
patients exposed in Europe and North America.
Ten additional data collection days (starting on 04-03-2020, ending on
04-14-2020) lead to more than twice the samples, and the results for the
latter date are shown in Figure 3.1 along with the standard deviations of
the estimators. Note that in order to estimate the variance of an estimator,
one needs to subsample the data which requires more samples to start with;
hence, the standard deviation is only evaluated for all samples available by 04-
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14-2020. The additional data samples show that the N region of the SARC-
Cov-2 genome exhibits a much more significant increase in mutations than
could have been predicted from early small-set sample sizes, amounting to
roughly an average of 23% of the genome, across populations. This finding is
significant as it suggests that genomic regions used as identifiers for the virus
may mutate much faster than predicted based on small preliminary sample
set information. Nevertheless, the N1 and N2 regions used as primer targets
for RT-PCR testing (the use of region N3 as a primer has been discontinued)
appear to be largely unmutated. This is illustrated in the Additional Table
C.11 which lists a total of only 8 mutations observed in these regions in the
SARS-Cov-2 genomes of US patients. Similar results for mutations in viral
genomes of patients from China are presented in Additional Table C.12.
Table 3.7 provides results for a finer partition of test samples into two
categories, one including males over 55 years of age and another females
below 55 years of age, with both populations sampled from Europe. The first
category has been empirically observed to be at higher risk of infection and
for exhibiting more severe symptoms [22]. Substantial mutational differences
are observed in the ORF1b, S and ORF10 regions. The differences in the
ORF1b and ORF10 genes appear to be mostly gender specific, while the
age factor may contribute to the differences in the mutation rates of the S
region. Another important finding is that the mutational support of ORF1b
is almost twice as large in the low risk population compared to the high risk
population. This result may imply that the large mutational support is a
result of a highly competitive virus-host interaction which forces the virus to
mutate the proteins encoded by ORF1b in order to gain an advantage over
the host’s immune system.
Figure 3.1 shows the mutational support sizes, along with the standard
deviations of the estimates for six different patient categories. Since the true
distribution of mutations of various groups of patients is not known, one can-
not directly calculate the standard deviation of the support sizes produced by
our estimator. To compute the standard deviation, we therefore subsample
85% of the available samples and compute the support size for the returned
aggregate mutation profile. Our samples are chosen randomly and uniformly
over the whole period of data collection, and for each month of data collec-
tion samples are retrieved separately and in proportion to the total number
of samples available for that month. Since the number of samples collected
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and made available during the months of December and January is small,
we group these two months together in the subsampling process. Subsam-
pling is repeated 100 times resulting in 100 aggregate mutation profiles and
corresponding support size estimates.
The mutational supports generated by our procedure have variances that
demonstrate good concentration of the estimates; some exceptions exist,
though, and are most likely not a consequence of the estimation procedure it-
self but rather an indicator of disparately collected datasets or some unknown
governing biological process. The latter is supported in part by previously
observed high rates of mutations in certain SARS-Cov-2 genes [45, 46]. The
results for ORF8 are particularly interesting because the corresponding stan-
dard deviations of the mutational support vary significantly across different
categories of patients: The standard deviation of the support size is close to
200 times higher for patients above 55 years of age than patients below 55
years of age.
We also performed a collection of tests in which alignments and mu-
tational counts were performed with respect to the first sample from the
same geographical region. Hence, for patients from Asia, the alignments
and mutation counts are still performed with respect to the genome of the
Wuhan-Hu-1 patient. For NA, we used the sample USA/WA1/2020 with ID
EPI ISL 404895, while for Europe we used the sample France/IDF0372/2020
with ID EPI ISL 406596, both being the chronologically first samples from
NA and Europe available at GISAID. For this study, we only used samples
retrieved by 04-14-2020. The results are available in Additional Tables C.4-
C.7. As expected, the mutational support estimates are lower for both the
NA and European sample sets. However, one important and interesting ex-
ception pertains to the estimates for the gene N regions and samples from
Europe, as well as samples for males above 55 from Europe, which are higher
for the alignment and mutation counts performed with respect to Patient
1 in Europe. The same is true for mutational support estimates for gene
N and under gender stratification. Additional differences were observed in
the mutational support of the ORF6a and ORF7 regions in younger females
versus older males when focusing on patients from Europe only and when us-
ing Patient 1 from Europe as the alignment reference. These results suggest
different mutational patterns for viruses hosted by high-risk populations in
Europe versus those in NA and Asia.
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Table 3.7: Support size differences between males above 55 years of age and
females below 55 years of age from Europe based on 1, 078 samples in each
group. The data was retrieved from GISAID by 04-14-2020. The
mutational supports between the two groups differ substantially for genes
with values shown in italics. ORF1ab and N are shown in bold due to their
large length and relevance in testing, respectively. Maximum support for all
the genes is the same as shown in previous tables.
Gene ML RWC RWC-S
Symbol M, > 55 F, < 55 M, > 55 F, < 55 M, > 55 F, < 55
ORF1a 588 670 1,159 1,374 1,078 1,294
ORF1b 349 553 686 1,189 638 1,117
S 209 166 420 329 387 296
ORF3a 76 61 138 104 124 96
E 10 9 17 15 16 14
M 27 33 45 58 40 52
ORF6 15 28 25 47 24 48
ORF7a 31 23 54 36 52 36
ORF8 27 28 45 48 43 46
N 110 108 197 199 178 183
ORF10 27 5 28 7 33 7
It is important to note that for some genes and patient categories it appears
the RWC estimates roughly double those of the ML estimator, but this is
not a general trend of the analysis. For example, the mutational support
estimates for ORF8 for male and female are approximately equal to ML
estimates (Table 3.5) and more pronounced differences exist across the whole
subpopulation spectrum. Similar trends are observed for ORF6 in Asian
subjects, and ORF10 across different subpopulations. Furthermore, although
the naive ML estimates may lead to similar conclusions regarding
the trends of mutations in some ORFs, the degree of the trend
and the scale of the mutation rates within different regions cannot
be fully understood through the use of ML estimates only. As an
illustrative example, the ML estimator implies that there is no difference in
the mutational supports of the ORF8 region in young versus old patients
(Table 3.4), as the values equal 340 and 341, respectively. On the other
hand, the RWC-S estimator predicts mutational supports of 236 and 343,
respectively, which show a very different stratification.
We conclude by pointing out that one way to validate the results for our
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support estimation methods is to compare the results of the ML mutation
counts at a later date with the computed estimates. We compare the mu-
tational supports using the small-sample techniques and the data collected
by 04-10-2020 with the actual count (ML estimates) generated from data re-
trieved by 04-14-2020. In this time period, the number of samples increased
by roughly 3, 000, as may be seen from Table 2.1. The results are listed in
Table 3.8. As may be seen, the estimates obtained based on data acquired
by 04-10-2020 for Europe and NA and all open reading frames are excellent
matches for the actual counts obtained by 04-14-2020, indicating that the
number of samples was sufficient to predict the growth trend. Much more
significant differences are observed for Asia, which can clearly be attributed
to the very small sample sizes available from that continent on both 04-10-
2020 and 04-14-2020 or potential strong correlations between the mutations
in the three aforementioned regions. Other categories that are of interest in-
volve male/female patients for which the actual counts from 04-14-2020 are
significantly smaller than the estimates. This is indicative of a large number
of potentially unseen mutations harbored by these populations.
Finally, Table 3.9 shows the support estimates for samples from patients
from Asia for a more recent date of data collection, 10-20-2020. In this case,
almost 10, 000 samples from Asia were readily available which allows one to
get significantly improved results for ML estimators. As may be seen, the
differences between ML and RWC-S values are significantly smaller, and for
some reason even close to equal when a very different trend was true for
data collected in April. In particular, the ratio of the number of estimated
mutations in the ORF E region for the RWC-S and ML method was close
to 1.76 in April, and only 1.24 in October. Similar findings are apparent for
other ORFs.
3.2 Distribution estimation
Next, we report on the distribution of mutations in the ORF1a,b and N re-
gions of the SARS-Cov-2 virus obtained using the Good-Turing estimator
and once again focus on the traits of different subpopulations. We focus
on these regions as the first two regions are the longest genes while the N
region is of importance for Covid-19 testing in NA. As may be seen from
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Table 3.8: Comparison of small-sample estimates of RWC-S based on data
retrieved by 04-10-2020 and the ML estimates based on data retrieved by
04-14-2020.
Gene Method-Date Asia Europe NA > 55 < 55 Male Female
ORF1a
RWC-S (04-10) 1,725 919 874 1,896 1,743 2,055 2,175
ML (04-14) 835 911 804 1,488 1,439 1,478 1,456
ORF1b
RWC-S (04-10) 611 491 432 924 896 941 1,621
ML (04-14) 316 477 403 787 953 705 991
S
RWC-S (04-10) 340 293 243 458 501 509 519
ML (04-14) 188 246 209 431 400 405 389
ORF3a
RWC-S (04-10) 168 85 63 171 124 190 158
ML (04-14) 93 99 81 156 165 169 140
E
RWC-S (04-10) 65 21 24 36 32 36 22
ML (04-14) 36 15 15 43 26 30 36
M
RWC-S (04-10) 52 35 27 92 77 82 94
ML (04-14) 31 51 28 79 62 67 69
ORF6
RWC-S (04-10) 3 86 25 64 41 74 50
ML (04-14) 3 52 21 53 32 50 40
ORF7a
RWC-S (04-10) 214 116 93 103 49 71 84
ML (04-14) 109 66 135 86 66 68 72
ORF8
RWC-S (04-10) 339 29 31 236 343 344 345
ML (04-14) 340 32 29 341 343 343 342
N
RWC-S (04-10) 91 108 129 223 265 226 259
ML (04-14) 60 139 138 201 219 195 204
ORF10
RWC-S (04-10) 17 48 10 39 50 32 19
ML (04-14) 11 30 10 35 33 31 13
Figures 3.2 and 3.3 there is a surprisingly small difference in the distribution
of the top-20 mutated sites across different age and gender groups, except for
a marked difference in the largest probability (in particular, in the N region
for populations partitioned according to age and populations partitioned ac-
cording to gender when including larger sample sets from 04-14-2020 as seen
in Figure B.2). This is especially the case for samples partitioned according
to gender, despite the fact that the number of mutations in female subjects
in the ORF1b region was close to twice as large as that in male subjects.
In addition, the probability of having a mutation at the highest probabil-
ity sites is significantly larger in “younger” than “older” populations. The
trend remains the same for data collected by 04-14-2020 as supported by
the results in Figure B.2. Figure B.3 gives similar results for alignment per-
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Table 3.9: ML and RWC-S estimates for mutational support in ORFs of
patients from Asia based on data collected by 10-20-2020. At that date,
substantially more samples (9, 271) were available for analysis. The
standard deviation values are given in parentheses.
ORF1a ORF1b S ORF3a E M
ML
5,020 2,691 1,418 464 115 188
(77) (42) (27) (19) (3) (4)
RWC-S
8,481 4,435 2,227 674 143 262
(152) (80) (61) (34) (5) (8)
ORF6 ORF7a ORF8 N ORF10
ML
90 304 363 510 45
(3) (9) (1) (6) (2)
RWC-S
112 333 361 711 61
(7) (15) (7) (14) (3)
formed against the first sequenced patient from each region. The situation
is completely different when comparing the distributions of mutations across
different geographic regions (Figure 3.4), where there are significant differ-
ences in the distributions as one would expect. To compactly summarize
the differences in the distributions, we also computed all three pairwise sym-
metric Kulback-Leibler (KL) divergences for the normalized top-20 mutation
probabilities as described below. We also list the Jaccard distances between
the sets of 20 most frequently mutated sites.
The distributions of mutations only reveal the statistical landscape of the
mutation sites but not their exact locations in the genome. The actual mu-
tated sites in the SARS-Cov-2 genomes are depicted in Figures 3.5 and 3.6, in
addition to a more detailed set of results presented in the Figures B.4 and B.5.
We selected the latest retrieval data for this analysis as it most accurately
reflects the positions undergoing most frequent mutations; we also focused on
two cohorts of patients for which the mutational landscapes differ the most.
The positional stratification of mutations is significant for patients from dif-
ferent continents, especially in the N region of the SARS-Cov-2 genome. The
largest spread of probability mass is (as expected) observed for patients from
Asia which is indicative of the larger exploration rate for mutations in the
region where the outbreak originated.
Additional Table C.8 lists the 10 most frequently mutated sites in the
ORF1a region of all previously analyzed patients categories when alignment
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(a) Mutations in the ORF1a region. (b) Mutations in the ORF1b region.
(c) Mutations in the N region.
Figure 3.2: Comparison of the estimated distributions of mutations in
adults <55 of age and adults >55 of age tested by 04-10-2020. Almost all
the probability mass is concentrated on five sites. The biggest observed
difference occurs in the N region.
is performed with respect to the first patient sequenced in the geographic
region. For the age and gender groupings, as expected, the top-ten sites
are the same except for one difference encountered in both cases (shown in
bold). A mutation in position 8, 781 of Asian and NA viral samples appears
with high frequency but is surprisingly not present in the list of top mutated
sites in the European population. Similarly, Additional Table C.9 lists the 10
most frequently mutated sites in the ORF1b region of all previously analyzed
patients categories. As one may expect from the differences in the mutational
support, the frequent sites of mutations differ significantly more in this region
for different age groups, gender and continents when compared to the ORF1a
region. This is especially the case when viewing the results for different
geographic regions as except for the top-ranked site and one more site (i.e.,
sites 14, 407 and 14, 804); all other locations are different. This suggests
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(a) Mutations in the ORF1a region. (b) Mutations in the ORF1b region.
(c) Mutations in the N region.
Figure 3.3: Comparison of the estimated distributions of mutations in male
and female test subjects tested by 04-10-2020. The distributions exhibit no
difference except on two sites in the N region.
very different evolution patterns of the virus in the ORF1b genomic region
at different regional sites, and more similar mutational patterns for different
gender and age categories. Additional Table C.10 suggests significantly fewer
stratifications in the mutations of different patient groups in the N region.
Gender and age do not appear to play a major role, but marked differences
are observed in patients from Asia, Europe and NA (the sites mutated in two
regions but not in the third are shown in italics). Given the large differences
in the mutational sites of patients across different continents in the N region it
comes as no surprise that different primers for RT-PCR testing were selected
for Asia, Europe and NA. The sites selected for forward and reverse primers
by the CDC, i.e., the N1 and N2 region, do not contain a significant number
of mutations, as may be easily seen from Additional Table C.11. Similar
observations are true for the primers selected in China (Additional Table
C.12).
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(a) Mutations in the ORF1a region . (b) Mutations in the ORF1b region.
(c) Mutations in the N region.
Figure 3.4: Differences in the estimated distributions of mutations for
different geographic regions based on subjects tested by 04-10-2020. The
distributions differ significantly.
Summarizing the Differences in the Distributions Using the
Symmetric KL Divergence and the Jaccard Distance
The symmetric KL divergence between two discrete probability distributions
p and q is defined as







For the mutation distributions pertaining to Europe-NA, Europe-Asia and
Asia-NA, the KL divergences equal 0.672, 0.316 and 0.376 (ORF1a), 0.491,
0.435 and 0.646 (ORF1b), 0.293, 1.021 and 0.303 (N), respectively, for data
collected by 04-14-2020. These results indicate that the largest differences in
the distributions in the ORF1a region exist between Europe and NA, while
the largest differences in the ORF1b region exist between Asia and NA. For
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Figure 3.5: Positions of mutations in the SARS-Cov-2 genome for patients
across three different continents, for data collected by 04-14-2020. The
height of the bar is proportional to the estimated probability of mutation.
Figure 3.6: Positions of mutations in the SARS-Cov-2 genome for European
females of age < 55 and males of age > 55 collected by 04-14-2020. The
height of the bar is proportional to the estimated probability.
the N region, a significant difference between the distributions of mutations is
observed between Europe and Asia, and at this point, no simple explanation
for this finding is possible. Similarly, the corresponding KL divergences based
on the samples collected by 04-10-2020 equal 0.788 (which is significantly
larger than the one predicted based on data collected on 04-14-2020), 0.328
and 0.371 (ORF1a), 0.743 (which is significantly larger than the one predicted
based on data collected on 04-14-2020), 0.615 and 0.0.755 (ORF1b), 0.315,
0.893 and 0.248 (N), respectively. The results for the KL divergences for the
N regions suggest relatively small changes in the distribution of mutations in
the N region, and larger changes in the ORF1a and ORF1b regions, which
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is expected.
Since the previously described distribution estimates do not convey the
information about the locations of the highest mutated sites but only their
frequency of mutations, we also list the Jaccard distances of the sets of mu-
tations specific to each tested subpopulation. For two sets Σ1 and Σ2 over





As may be seen from Table 3.10, the largest distances are observed in
the E and ORF10 regions, in the first case when comparing patients from
Asia and Europe and in the second case when comparing younger female and
older males in Europe. The distances in the N region seem to be significantly
smaller, especially between the two categories of patients from Europe. The
results for the ORF10 region are rather surprising as they indicate the high-
est possible difference is observed between males and females on the same
continent despite these differences being uniformly small for all other open
reading frames. As already pointed out, the function of the ORF10 reading
frame is currently unknown but given the marked mutational profiles in high-
risk and low-risk profiles it is highly likely that this gene plays an important
role in guiding disease symptoms. The exact same trends are observed when
using alignments with respect to Patient 1 from the underlying geographic
region, as listed in Additional Table C.13.
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Table 3.10: The Jaccard distance between sets of mutations from different
pairs of geographic regions, based on alignments with respect to Patient 1
from Wuhan. Values in italics are the smallest in the category, while values
in bold are the largest.
ORF1a ORF1b S ORF3a E M
Asia - Europe 0.91 0.95 0.91 0.92 0.98 0.92
Europe-NA 0.88 0.89 0.88 0.84 0.89 0.89
Asia - NA 0.91 0.95 0.92 0.95 0.91 0.89
Male >55 - Female
< 55 (Europe)
0.85 0.87 0.85 0.73 0.88 0.75
ORF6 ORF7a ORF8 N ORF10
Asia - Europe 0.96 0.74 0.91 0.86 0.89
Europe-NA 0.86 0.91 0.89 0.82 0.95
Asia - NA 0.96 0.89 0.92 0.87 0.89
Male >55 - Female
< 55 (Europe)




The problem of determining mutational support and distribution of a virus
is crucial for accessing its virulence and for primer selection for real time
RT-PCR kits, especially during early stages of a pandemic when insufficient
information is available about the virus. An accurate estimate of possible
mutations in the viral genome in the absence of a sufficiently large database
is important for an early understanding of the adaptation mechanisms em-
ployed by the virus as well as the potential differences in its impact on diverse
subpopulations. In this thesis, we presented a novel, state-of-the-art estima-
tor for support estimation for the small-sample regime and benchmarked it
against existing estimators. We also adapted the Good-Turing estimator for
distribution estimation.
We used our estimators for a differential analysis on mutations in the
SARS-Cov-2 genome among various population groups including male/female,
older/younger and different geographic locations. We observed significant dif-
ferences in the mutational support of ORF6 and ORF7a between older and
younger patients as well as differences in ORF1b and ORF10 between males
and females. We also noted that these differences persist with increase in
number of samples available. Given that these ORFs play important biologi-
cal roles in the spread and evolution of the virus, these differences can provide
significant insights into why different population groups are impacted differ-
ently by the virus. Furthermore, we discovered differences in mutational
support among all ORFs while comparing between different geographical
locations. Our analysis showed that patients from Asia had comparatively
higher mutational support than those from Europe and North America, which
can potentially indicate that the virus was in circulation much earlier than
expected. We validated our results by comparing the support estimate re-
turned by our estimators on 04-10-2020 with ML estimates from 04-14-2020
as well as comparing the two estimators on a much larger sample set obtained
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on 10-20-2020.
We observed that even though the N region of the SARS-CoV-2 genome has
a high number of mutations, only a few mutations lay in the primer regions
for real time RT-PCR kits recommended by CDC for testing in the USA.
This is important because frequent mutations in the primer regions can po-
tentially lead to high rates of false negative results. Finally, we compared the
distributions of mutations among various population groups and computed
pairwise symmetric Kulback-Leibler divergences for normalized top-20 mu-
tated positions as well as Jaccard distance for the sets of all mutations for
each population. We emphasize that our estimators are general enough to be
adapted for the genomes of any microorganism, making it extremely useful




A.1 Proof of the theorem establishing the length of the
optimization interval
To prove the result, we need to show that ∀λ ≥ 6.5L, ∂
∂λ
g(a, λ) < 0. The





















Clearly, the right-hand side in the above expression is negative for all λ > L.











































To analyze the two terms of the derivative, we introduce the vectors y, z,1








− 1), ( 1
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− 1), ..., (L
λ
− 1))T ,
1 = (1, 1, ..., 1)T ,







































D + (1zT + z1T )
)
y.
To show that ∂
∂λ
g(a, λ) < 0 for all polynomials of degree L whenever λ > CL,




D + (1zT + z1T )
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is negative-definite whenever
λ > CL, for some constant C > 0. It suffices to show that the sum of the
maximum eigenvalues of e
λ
k




diagonal matrix. Thus, we turn our attention to determining the maximum
eigenvalues of these two matrices. For e
λ
k























. When λ > L, it is clear that i!
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The last inequality is a consequence of Stirling’s formula, which asserts that
n! ≥ (n
e



















Next, we derive an upper bound on maximum eigenvalue of the second ma-
trix. The i, j entry of the matrix (1zT + z1T ) equals i+j−2
λ
− 2, and all these
values are negative when λ > L. Moreover, it is clear that the matrix of
interest has rank equal to 2. Therefore, the matrix has exactly two nonzero
eigenvalues.
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Let A = −(1zT + z1T ). All entries of A are positive whenever λ > L. By
Gershgorin’s theorem, we can upper bound the maximum eigenvalues of the
matrix A by its maximum row sum. It is obvious that the maximum row
sum equals
2(L+ 1)− L(L+ 1)
2λ
.
Moreover, the trace of A equals
2(L+ 1)− L(L+ 1)
λ
.
This implies that the minimum eigenvalue of A is lower bounded by −L(L+1)
2λ
,




Summing up the two previously derived upper bounds gives





















⇔ log(L) + log(L+ 1) + log(k)− L log(L) + L < λ+ log(λ)− L log(λ).
(A.1)




(λ+ log(λ)− L log(λ)) = 1− L− 1
λ
.
By the definition of L = bc0 log(k)c, we also have log(k) ≤ L+1c0 . Using
log(x + 1) ≤ x, which holds ∀x ≥ 1. Hence ∀λ > CL where C > 2, the




− L log(L) + L < CL+ log(CL)− L log(CL).
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Rearranging terms leads to(












) > 0. The first condition implies C ≥ e
1
c0 = 6.0021,
while the second condition holds with C = 6.5, for which the first condition
is also satisfied. This completes the proof.
A.2 Proof of the convergence rate of the discretized
SIP
The proof consists of two parts. In the first part, we establish the conditions
for convergence, while in the second part, we determine the convergence rate.
For simplicity, we present the proofs for the case without Poisson repeats.
We then outline how the analysis can be modified to account for the repeats.
A.2.1 Proof of convergence
We start by introducing the relevant terminology. Let Π ⊂ RL+1 be a closed
set of parameters, and let f be a continuous functional on Π. Assume that
B ⊂ R is compact and that g : Π 7→ C(B) is a continuous mapping from Π
into C(B), where C(B) is the space of continuous functions over B equipped
with the supremum norm || · ||∞. For each D ⊂ B let
M(D) = {c ∈ Π| g(c, x) ≤ 0, x ∈ D}
denote the set of feasible points of the optimization problem
min f(c) over c ∈M(D).
Assuming that M(D) 6= ∅, let
µ(D) = inf{f(c)|c ∈M(D)},
48
and define the level set
Level(c0, D) = {c ∈ Π| f(c) ≤ f(c0)} ∩M(D).
We also make the following two assumptions:
 Assumption 1: Fine grid Let N0 = N ∪ {0}. There exists a sequence
{Bi} of compact subsets of B with Bi ⊂ Bi+1, i ∈ N0, for which
limi→∞ h(Bi, B) = 0, such that





 Assumption 2: Bounded level set M(B) is nonempty, and there exists
a c0 ∈M(B) such that the level set Level(c0, B0) is bounded and hence
compact in RL+1.
Convergence of the discretized method, Theorem 2.1 from [33]:
Under Assumptions 1 and 2, the solution of the discretized problem con-
verges to the optimal solution. More formally, we have




If c∗ is the unique optimal solution of the original problem, and c∗i is the
optimal solution of the discretized relaxation with grid Bi, then
lim
i→∞
||c∗ − c∗i ||2 = 0.
It is straightforward to see that our chosen grid is arbitrary fine. Hence, we
only need to prove that there exists a c0 such that the level set Level(c0, D)
is bounded.
Let c = (a; t) and note that in our setting, f(c) = t. Rewrite g(c, λ) in
matrix form as
g(c, λ) = aTM(λ)a + aTΛΛTa− t,
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where
Λ , e−λ(λ0, λ1, ..., λL)T .
Note that only a1, ...aL are allowed to vary since we fixed a0 = −1. Obviously,
ΛΛT is positive semi-definite and the previously introduced M(λ) is positive
definite for all λ > 0. Since the constraints on g are positive definite with
respect to a1, ...aL, g is coercive in a1, ...aL. Furthermore, for any given t,
the set of feasible coefficients a1, ...aL is bounded. Therefore, given a t0, the
level set Level(c0, B0) is bounded. This ensures that Assumption 1 holds for
our optimization problem.
Next, we prove the uniqueness of the optimal solution c?. Note that prov-
ing this result is equivalent to proving the uniqueness of a?. Hence, we once














Clearly, ∀λ ∈ [n
k
, 6.5L], the function hλ(a) is strictly convex since (M(λ) +
ΛΛT )  0, ∀λ ∈ [n
k
, 6.5L]. Taking the supremum over λ preserves strict






















,6.5L] hλ(a) is strictly convex, which consequently implies the
uniqueness of a? and hence c?.
For the case of samples passed through a Poisson channel, it is not hard to


























respectively. Thus, a similar analysis is possible and the details are omitted.
The proof above along with the previous observation proves the convergence
result.
A.2.2 Proof for the convergence rate
In what follows, and for reasons of simplicity, we omit the constraint a0 = −1
in the SIP formulation. The described proof only requires small modifications
to accommodate a0 = −1.
Recall that we used Bd to denote the grid with grid spacing d. In order to
use the results in [34], we require the convergence assumptions below.
 Assumption 3: Let c̄ be a local minimizer of an SIP. There exists a local
solution cd of the discretized SIP with grid Bd such that
||cd − c̄|| → 0.
This assumption is satisfied for the SIP of interest as shown in the first
part of the proof.
 Assumption 4: The following hold true:




is continuous on Ū ×B.
– The set B is compact, nonempty and explicitly given as the so-
lution set of a set of inequalities, B = {λ ∈ R|vi(λ) ≤ 0, i ∈ I},
where I is a finite index set and vi ∈ C2(B).
– For any λ̄ ∈ B, the vectors ∂
∂λ
vi(λ̄), i ∈ {i ∈ I|vi(λ̄) = 0} are
linearly independent.
Recall that our objective is of the form
g(c, λ) = aTM(λ)a + aTΛΛTa− t,
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where




Diag(λ00!, λ11!, ..., λLL!).
It is straightforward to see that the first condition in Assumption 4
holds. For the second condition, recall that B = [n
k
, 6.5L]. Hence,
the second condition can be satisfied by choosing I = {1}, v1(λ) =
(λ − n
k
)(λ − 6.5L). Since we only have one variable v1, it is also easy
to see that the third condition is met.
 Assumption 5: The set B satisfies Assumption 4 and all the sets Bd
contain the boundary points n
k
, 6.5L.
This assumption also clearly holds for the grid of choice. Note that
it is crucial to include the boundary points for the proof in [34] to be
applicable.
 Assumption 6: ∇cg(c, λ) is continuous on Ū × B, where Ū is a neigh-
borhood of c̄. Moreover, there exists a vector ξ such that
∇cg(c̄, λ)T ξ ≤ −1, ∀λ ∈ B.
Note that ∇cg(c, λ) = [∇ag(c, λ);∇tg(c, λ)] and
∇ag(c, λ) = 2(M(λ) + ΛΛT )a.
Also note that ∀λ ∈ B, M(λ)+ΛΛT is positive definite. Hence choosing
ξ to be colinear with and of the same direction as [−aT 1]T , as well as
of sufficiently large norm, will allow us to satisfy the inequality
∇cg(c̄, λ)T ξ ≤ −1, ∀λ ∈ B.
Hence, Assumption 6 holds as well. The next results follow from the
above assumptions and observations, and the results in [34].
(Corollary 1 in [34]) Let td be the optimal objective value of the discretized
SIP used for support estimation with the grid Bd, and let t
? be the optimal
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objective value for the original SIP. Since Assumptions 3-6 hold, then for
some c3 > 0 and d sufficiently small, we have
0 ≤ t? − td ≤ c3d2.
Consequently, td → t? with a convergence rate of O(d2).
(Theorem 2 in [34]) Assume that all assumptions in Corollary 1 above
hold. If there exists a constant c4 > 0 such that
t− t̄ ≥ c4||c− c̄||, ∀c ∈M(B) ∩ Ū ,
then for sufficiently small d and σ > 0 we have
||cd − c̄|| ≤ σd2.
This result implies that if c̄ is also a strict minimum of order one, then
the solution of the discretized SIP converges to that of the original SIP with
rate O(d2). For the Poisson repeat channel, the constraints are also strictly
convex in a. Therefore, a similar analysis is possible and the details are
omitted once again. Combining these results completes the proof.
A.3 Additional theoretical results
The result described in the main text follows from Theorem 6.2 in [24].
(Theorem 6.2 from [24]) Let W (x) = exp(−Q(x)) be a weight function,
where Q : R 7→ [0,∞) is even, convex, diverging for x→∞, and such that
0 = Q(0) < Q(x), ∀x 6= 0.
Then, for any polynomial P (x) of degree ≤ L, not identical to zero, one has
sup
x∈R





|P (x)W (x)| < sup
x∈[−ML,ML]
|P (x)W (x)|.
Here, ML stands for the Mhaskar-Rakhmanov-Saff (MSF) number, which is
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In our setting, the weight equals exp(−x). Solving (A.3) gives us an MSF
number equal to ML =
π
2















A.4 Construction of the RWC-S estimator


















































































































where the last inequality is due to the fact that Ŝc ≤ S. Note that the
only difference between (A.4) and the corresponding optimization problem
described in the main text is in terms of changing the normalization from 1/k
to 1/Ŝc in the first term. The expression (A.4) is optimized by the solution



























This appendix provides additional figures and results.








































































































































Figure B.1: Comparison of performance of various estimators on non-i.i.d.
data with ground truth. The results are obtained over 100 independent
trials. (a) and (b) show the mean and standard deviation of the estimators,
while (c) and (d) show the MSE normalized by S2.
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Figure B.2: Comparison of mutations in various groups of patients based on
the data collected by 04-14-2020. All the alignments were performed with
respect to Patient 1 Wuhan-Hu-1.
57
Figure B.3: Comparison of mutations in various groups of patients based on
the data collected by 04-14-2020. All the alignments were performed with
respect to the first sequenced patient 1 in the corresponding region.
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Figure B.4: Positions of mutations in the SARS-Cov-2 genome with high
probability of mutations in patients from different categories based on data
collected by 04-14-2020. The height of the bar is proportional to the
probability of the mutation. All the alignments were performed with
respect to Patient 1 Wuhan-Hu-1.
Figure B.5: Positions of mutations in the SARS-Cov-2 genome with high
probability of mutations in patients from different categories based on data
collected by 04-14-2020. The height of the bar is proportional to the
probability of the mutation. All the alignments were performed with








[1] R. Sanjuán, M. R. Nebot, N. Chirico, L. M. Mansky, and R. Belshaw,
“Viral mutation rates,” Journal of Virology, vol. 84, no. 19, pp. 9733–
9748, 2010.
[2] J. W. Drake and J. J. Holland, “Mutation rates among RNA viruses,”
Proceedings of the National Academy of Sciences, vol. 96, no. 24, pp.
13 910–13 913, 1999.
[3] R. Sanjuán and P. Domingo-Calap, “Mechanisms of viral mutation,”
Cellular and Molecular Life Sciences, vol. 73, no. 23, pp. 4433–4448,
2016.
[4] S. Duffy, L. A. Shackelton, and E. C. Holmes, “Rates of evolutionary
change in viruses: Patterns and determinants,” Nature Reviews Genet-
ics, vol. 9, no. 4, pp. 267–276, 2008.
[5] T. Hoenen, D. Safronetz, A. Groseth, K. Wollenberg, O. Koita, B. Di-
arra, I. Fall, F. Haidara, F. Diallo, M. Sanogo et al., “Mutation rate and
genotype variation of Ebola virus from Mali case sequences,” Science,
vol. 348, no. 6230, pp. 117–119, 2015.
[6] R. M. Ribeiro, H. Li, S. Wang, M. B. Stoddard, G. H. Learn, B. T.
Korber, T. Bhattacharya, J. Guedj, E. H. Parrish, B. H. Hahn et al.,
“Quantifying the diversification of hepatitis c virus (HCV) during pri-
mary infection: estimates of the in vivo mutation rate,” PLoS Pathogens,
vol. 8, no. 8, 2012.
[7] J. J. Bull, R. Sanjuan, and C. O. Wilke, “Theory of lethal mutagenesis
for viruses,” Journal of Virology, vol. 81, no. 6, pp. 2930–2939, 2007.
[8] R. Sanjuán, A. Moya, and S. F. Elena, “The distribution of fitness effects
caused by single-nucleotide substitutions in an RNA virus,” Proceedings
of the National Academy of Sciences, vol. 101, no. 22, pp. 8396–8401,
2004.
[9] A. Acevedo, L. Brodsky, and R. Andino, “Mutational and fitness land-
scapes of an RNA virus revealed through population sequencing,” Na-
ture, vol. 505, no. 7485, pp. 686–690, 2014.
61
[10] C. L. Burch and L. Chao, “Evolvability of an RNA virus is determined
by its mutational neighbourhood,” Nature, vol. 406, no. 6796, pp. 625–
628, 2000.
[11] K. M. Peck and A. S. Lauring, “Complexities of viral mutation rates,”
Journal of Virology, vol. 92, no. 14, pp. e01 031–17, 2018.
[12] Centre for Health Security, Johns Hopkins University, “SARS-CoV-2
genetics,” https://www.centerforhealthsecurity.org/resources/COVID-
19/COVID-19-fact-sheets/200128-nCoV-whitepaper.pdf, 2020.
[13] W. A. Gale and G. Sampson, “Good-Turing frequency estimation with-
out tears,” Journal of Quantitative Linguistics, vol. 2, no. 3, pp. 217–237,
1995.
[14] A. Orlitsky and A. T. Suresh, “Competitive distribution estimation:
Why is Good-Turing good,” in Advances in Neural Information Pro-
cessing Systems, 2015, pp. 2143–2151.
[15] Johns Hopkins University, “Covid-19 dashboard by the Center for Sys-
tems Science and Engineering (CSSE) at Johns Hopkins University
(JHU),” https://coronavirus.jhu.edu/map.html, 2020.
[16] L. Mousavizadeh and S. Ghasemi, “Genotype and phenotype of COVID-
19: Their roles in pathogenesis,” Journal of Microbiology, Immunology
and Infection, 2020.
[17] GeneTex, “GeneTex review of the function of SARS-Cov-2 ORFs,”
https://www.genetex.com/MarketingMaterial/Index/SARS-CoV-
2 Genome and Proteome, 2020.
[18] Center for Disease Control and Diagnostics, “2019 novel coro-
navirus (2019-nCoV) real-time RT-PCR diagnostic panel,
catalog number 2019-nCoVEUA-01 with 1000 reactions,”
https://www.fda.gov/media/134922/download, 2020.
[19] Y. Shu and J. McCauley, “GISAID: Global initiative on sharing all in-
fluenza data–from vision to reality,” Eurosurveillance, vol. 22, no. 13,
2017.
[20] R. C. Edgar, “MUSCLE: A multiple sequence alignment method with
reduced time and space complexity,” BMC Bioinformatics, vol. 5, no. 1,
p. 113, 2004.
[21] J. Kopel, A. Perisetti, A. Roghani, M. Aziz, M. Gajendran, and
H. Goyal, “Racial and gender-based differences in COVID-19,” Fron-
tiers in Public Health, vol. 8, p. 418, 2020.
62
[22] R. C. Rabin, “Why the coronavirus seems to hit men harder
than women,” New York Times, 2020. [Online]. Available: https:
//www.nytimes.com/2020/02/20/health/coronavirus-men-women.html
[23] Y. Wu, P. Yang et al., “Chebyshev polynomials, moment matching, and
optimal estimation of the unseen,” The Annals of Statistics, vol. 47,
no. 2, pp. 857–883, 2019.
[24] D. S. Lubinsky, “A survey of weighted polynomial approximation with
exponential weights,” Surveys in Approximation Theory, vol. 3, pp. 1–
105, 2007.
[25] L. Paninski, “Estimation of entropy and mutual information,” Neural
Computation, vol. 15, no. 6, pp. 1191–1253, 2003.
[26] P. Valiant and G. Valiant, “Estimating the unseen: Improved estimators
for entropy and other properties,” in Advances in Neural Information
Processing Systems, 2013, pp. 2157–2165.
[27] A. Orlitsky, N. P. Santhanam, and J. Zhang, “Always Good-Turing:
Asymptotically optimal probability estimation,” Science, vol. 302, no.
5644, pp. 427–431, 2003.
[28] A. F. Timan, Theory of Approximation of Functions of a Real Variable.
Elsevier, 2014, vol. 34.
[29] J. C. Mason and D. C. Handscomb, Chebyshev Polynomials. Chapman
and Hall/CRC, 2002.
[30] S. Boyd and L. Vandenberghe, Convex Optimization. Cambridge Uni-
versity Press, 2004.
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